News
Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...
The FDA has started an accelerated review of Eisai and Biogen's a new amyloid-targeting antibody lecanemab for Alzheimer's disease, with a 6 January deadline that keep them ahead of closest
